DNASTAR® has announced that it has received a Fast-track Phase I and Phase II SBIR grant award from the National Institutes of Health entitled, “Association Analysis Software for Mining Clinical Next-Gen Sequencing Data”.
The funding will support the company’s research and development aimed at expanding its industry-leading sequence assembly and analysis software from broad research usage to the clinical research market.
Tom Schwei, Vice President and General Manager of DNASTAR, commented, “DNASTAR has been a leader in providing sequence assembly and analysis software to life scientists for more than 25 years. The funding under this grant program will be used to accelerate the speed with which we can move from the general research market into the clinical research market. We already have a strong foundation on which to build our clinical research software platform. This new funding will help us move quickly to add key functionality sought by clinical researchers.
“In addition, this grant project will involve several clinical trial studies with numerous collaborators and clinical trial sponsors. We anticipate sequencing hundreds of samples in a number of studies as part of this Fast-track grant project to help address some of the most pressing needs in some key disease areas. This will help ensure that our software meets the needs of clinical researchers in the best possible way.”
Schwei concluded, “This project ties in well with DNASTAR’s long-term strategy, which is to build on our strength in sequencing software for the general research market and expand into a wide range of related fields. Clinical research is but one of those very important areas we are addressing for the future.”